Takeda, LegoChem research ADCs; Takeda later gains rights for multiple immuno-oncology targets in $411mm license deal
LegoChem Biosciences Inc. and Takeda Pharmaceutical Co. Ltd. (through its Takeda Oncology/Millennium Pharmaceuticals unit) will together research and develop next-generation antibody-drug conjugates (ADCs) for cancer.
Drug Discovery Tools
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com